The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out ...

Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...